What does the evidence say about L-Citrulline Blood Flow Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for L-Citrulline Blood Flow Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Background: Post-COVID-19 syndrome is associated with endothelial dysfunction (ED) and various sequelae, particularly in individuals who experienced critical illness during the acute phase, affecting lung function and the musculoskeletal system. [Fernanda SM (2026); evidence level 2] - Conclusions: L-citrulline supplementation for three months decreased ICAM-1 and increased 6MWT. [Fernanda SM (2026); evidence level 2] - L-citrulline, a nonessential amino acid, has been shown to improve endothelial function, systemic inflammation, blood pressure, and physical performance. [Fernanda SM (2026); evidence level 2] - Data were analyzed using repeated-measures analysis of variance with appropriate post hoc adjustments, and statistical significance was set at P Results Compared with placebo, combined CITMAL + L-ARG supplementation significantly increased peak power output (747.85 ± 115.61 vs. [Uçar H (2026); evidence level 4] - 631.61 ± 108.40 W, P -1 , P P P -1 , P Conclusion The findings of this study indicate that combined L-ARG and CITMAL supplementation is associated with improvements in selected anaerobic performance, agility, and countermovement jump outcomes in highly trained taekwondo athletes. [Uçar H (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.